Atara Biotherapeutics stops development of kidney drug

Your Health Matters

(Reuters) – Atara Biotherapeutics Inc said it would stop developing its kidney drug after the treatment failed to meet the main goal of a mid-stage study. The drug developer said on Monday that the drug, PINTA 745, did not improve physical function, levels of inflammation and blood sugar in patients in the study. (Reporting by Vidya L Nathan in Bengaluru; Editing by Kirti Pandey)
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave